Compare BOW & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOW | XNCR |
|---|---|---|
| Founded | 2020 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.3M | 881.9M |
| IPO Year | 2024 | 2013 |
| Metric | BOW | XNCR |
|---|---|---|
| Price | $22.45 | $11.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $34.29 | $22.89 |
| AVG Volume (30 Days) | 217.8K | ★ 644.9K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.26 | ★ 65.36 |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $551,589,000.00 | $125,576,000.00 |
| Revenue This Year | $21.14 | N/A |
| Revenue Next Year | $19.15 | $6.52 |
| P/E Ratio | $14.11 | ★ N/A |
| Revenue Growth | ★ 29.58 | 13.65 |
| 52 Week Low | $21.93 | $6.92 |
| 52 Week High | $42.29 | $18.69 |
| Indicator | BOW | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 34.17 | 48.51 |
| Support Level | $22.15 | $10.92 |
| Resistance Level | $26.45 | $12.73 |
| Average True Range (ATR) | 1.17 | 0.90 |
| MACD | -0.26 | 0.04 |
| Stochastic Oscillator | 12.04 | 34.18 |
Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity and hospitality segments and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.